K
Kadmon
Developing therapies for immune disorders, fibrotic diseases and cancer
About Kadmon
Kadmon, a Sanofi Company, is a biopharmaceutical firm based in New York, NY, specializing in the discovery, development, and marketing of transformative therapies. The company focuses on addressing serious unmet medical needs, particularly in the areas of immune disorders, fibrotic diseases, and cancer. Kadmon's mission is to create innovative treatments that significantly improve patient outcomes where current therapies fall short.
Read full description
Kadmon serves a diverse range of clients, including patients, healthcare providers, and stakeholders within the global healthcare community. The company operates in the biopharmaceutical market, which involves the use of biological and chemical processes to develop drugs and therapies. This market is highly competitive and requires significant investment in research and development (R&D).
The business model of Kadmon revolves around its robust clinical pipeline, which includes several promising treatments currently under development. The company employs a structure-based drug design (SBDD) platform that integrates data from X-ray crystallography and molecular modeling. This advanced technology helps Kadmon to precisely target and develop new drugs more efficiently.
Kadmon generates revenue through the commercialization of its therapies. Once a drug successfully passes through clinical trials and receives regulatory approval, it is marketed and sold to healthcare providers and patients. The company may also enter into partnerships or licensing agreements with other pharmaceutical firms to expand the reach of its products.
In summary, Kadmon is dedicated to transforming the treatment landscape for immune and fibrotic diseases, as well as cancer, through innovative drug development and ethical business practices.
At a glance
- Founded
- 2009
- Headquarters
- New York City, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Kadmon.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series B and later1 investor entered at this stage
- APAcuta Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
44 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kadmon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kadmon on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.